Pfizer announces U.S. availability of biosimilar INFLECTRA
Pfizer announced that the company will begin shipment of INFLECTRA for injection, a biosimilar of REMICADE to wholesalers in the United States in late November 2016. INFLECTRA will be the first biosimilar monoclonal antibody and only the second biosimilar to be available in the U.S. "Biologics have revolutionized the treatment of many life-threatening and chronic diseases. By introducing INFLECTRA to the U.S. marketplace, Pfizer is helping customers access an additional high quality treatment option that promises greater savings for the healthcare system," said Diem Nguyen, regional president North America, Pfizer Essential Health Business. "We are proud of our global leadership in biosimilars, and will continue our efforts to advance a sustainable, competitive marketplace for these therapies to deliver a high quality, consistent supply of product and long-term savings and value for patients and physicians." Pfizer holds exclusive commercialization rights to Celltrion's INFLECTRA in the U.S., and has already successfully introduced INFLECTRA in other markets across the globe.